Skip to Content

Gabriel N. Hortobagyi, MD, FACP

Present Title & Affiliation

Primary Appointment

Professor of Medicine, Department of Breast Medical Oncology, Division of Cancer Medicine, UTMDACC, Houston, TX
Nellie B. Connally Chair in Breast Cancer, Department of Breast Medical Oncology, Division of Cancer Medicine, The University of Texas MD Anderson Cancer Center, Houston, TX
Program Director, Department of Breast Medical Oncology, Susan G. Komen Interdisciplinary Breast Fellowship Program, The University of Texas MD Anderson Cancer Center, Houston, TX

Education & Training

Degree-Granting Education

1970 Universidad Nacional de Colombia, Bogotá, Colombia, MD, Medicine
1963 Colegio Helvetia, Bogotá, Colombia, BS

Postgraduate Training

7/1975-6/1976 Clinical Fellowship, Medical Oncology, UT MD Anderson Hospital & Tumor Institute, Houston, TX
7/1971-6/1974 Clinical Residency, Internal Medicine, St. Luke's Hospital, Case-Western Reserve University, Cleveland, OH

Board Certifications

1/1977 American Board of Internal Medicine, Subspecialty
1/1975 American Board of Internal Medicine


Administrative Appointments/Responsibilities

Member, The University of Texas MD Anderson Cancer Center Department of Breast Medical Oncology Tenure Track Faculty Member Search Committee, Houston, TX, 8/2013-present
Member of the Internal Advisory Board, The University of Texas MD Anderson Cancer Center Center for Radiation Oncology Research (CROR), Houston, TX, 5/2013-present
Member of the Internal Advisory Board, The University of Texas MD Anderson Cancer Center Multidisciplinary Research Program, Houston, TX, 1/2013-present
Member Intermal Advisory Board, The University of Texas MD Anderson Cancer Center Cancer Prevention and Research Institute of Texas (CPRIT) Multiple Investigator Grant Application entitled “Novel Posttranslational Modifications and Functions of Kinases in Breast Tumor Progression”, P.I., Houston, TX, 11/2011-present
Member, The University of Texas MD Anderson Cancer Center Standing Committee on Faculty Awards, Houston, TX, 8/2011-present
Member of the Internal Advisory Board, The University of Texas MD Anderson Cancer Center Program Project "Growth Factor Receptor Signaling in Breast Cancer and Metabolic Regulation", P.I.: M-C Hung, Houston, TX, 6/2010-present
Department Chair, Department of Breast Medical Oncology, Division of Cancer Medicine, The University of Texas MD Anderson Cancer Center, Houston, TX, 7/1992-8/2012
Medical Director, Multidisciplinary Breast Cancer Research Program, UTMDACC, Houston, TX, 9/1991-9/2012

Honors and Awards

2013-2014 Best Doctors In America,
2013 America's Top Doctors, 12th Ed., 2013, Castle Connolly Medical, Ltd., New York, NY
2012 America’s Top Doctors, 11th Ed., 2012, Castle Connolly Medical, Ltd., New York, NY
2012 Breast Journal Club Award for Best Publication in Breast Oncology in 2012, Naples, Italy
2012 Honorary President, Breast-Gynecological Cancer Society
2012 Jill Rose Award, The Breast Cancer Research Foundation, New York, NY
2012 Texas Super Doctors, 2012, Texas Monthly, 40(12)S-24, 2012
2012 Top Doctors: Southeastern Texas, 1st Ed, Caste Connolly Medical, Ltd., New York, NY
2012 Top Medical Oncologists, Top Doctors, US News,
2012 Who is Who Magyarországon, (a member of the Hübners Who is Who), 10th Ed., 2012, Budapest, Hungary
2012 William L. McGuire Award and Memorial Lecture, CTCR-AACR San Antonio Breast Cancer Symposium
2011-present Houston's Top Doctors, H Texas Magazine
2011 Premio Dr. Jenaro Haddock (Dr. Jenaro Haddock Prize and Memorial Lecture), The Asociación de Hematología y Oncología Médica de Puerto Rico, San Juan, PR
2011 2011 Addarii Award and Lecture, (University of Bologna, Policlinico S. Orsola-Malpighi, Bologna, Italy)
2011 2011 Bob Pinedo Cancer Care Prize Award and Keynote Lecture, Society for Translational Oncology, Belfast, Northern Ireland, UK
2011 America’s Top Doctors for Cancer, 7th Ed., Castle Connolly Medical, Ltd., New York, NY
2011 Honorary Member, Tribute Committee of the Silver Rose Gala
2010-2011 Who’s Who in America, Marquis Who’s Who
2009-present John Mendelsohn Lifetime Scientific Achievement Award - Division of CancerMedicine., Division of Cancer Medicine, The University of Texas M.D. Anderson Cancer Center
2009-present Laurea Honoris Causa (doctor Honoris Causa, Honorary Doctorate in Medicine and Surgery), La Universidad Autonoma de Nuevo Leon, Monterrey Mexico
2009-2012 Charles A. LeMaistre Outstanding Achievement Award in Cancer, The University of Texas M.D. Anderson Cancer Center
2007 Cruz Civica Jorge Bejarano (Bronze Level), Government of Colombia
2003 Glenn Robbins Award, New York Metropolitan Breast Group/New York Cancer Society
2003 Horizon Scientific Achievement Award, Bristol-Myers Squibb and The Susan G. Komen Breast Cancer Foundation, Washington, DC
1999 Vermeille Medal of the City of Paris, (Vermeille), Paris, France
1997 Brinker International Award for Clinical Research, Susan G. Komen Breast Cancer Foundation, San Antonio, TX
1995 Cino del Duca Award, ICACT, Paris France

Professional Memberships

Academia Nacional de Medicina de Buenos Aires, Argentina, Argentina
Corresponding Member, 1993-present
Academia Nacional de Medicina, Mexico, Mexico
Corresponding Member, 1994-present
American Society of Clinical Oncology, Alexandria, VA
President, 5/2006-5/2007
Hungarian Academy of Sciences, Hungary
External Member-Medical Services Section, 2004-present
Southwest Oncology Group
Breast Committee Chair, 2007-present
The American Society of the French Legion of Honor
Member, 2001-present

Selected Publications

Peer-Reviewed Original Research Articles

1. Piccart M, Hortobagyi GN, Campone M, Pritchard KI, Lebrun F, Ito Y, Noguchi S, Perez A, Rugo HS, Deleu I, Burris HA, Provencher L, Neven P, Gnant M, Shtivelband M, Wu C, Fan J, Feng W, Taran T, Baselga J. Everolimus plus exemestane for hormone-receptor-positive, human epidermal growth factor receptor-2-negative advanced breast cancer: overall survival results from BOLERO-2. Ann Oncol 25(12):2357-62, 12/2014. e-Pub 9/2014. PMID: 25231953.
2. Smerage JB, Barlow WE, Hortobagyi GN, Winer EP, Leyland-Jones B, Srkalovic G, Tejwani S, Schott AF, O'Rourke MA, Lew DL, Doyle GV, Gralow JR, Livingston RB, Hayes DF. Circulating Tumor Cells and Response to Chemotherapy in Metastatic Breast Cancer: SWOG S0500. Accompanied by an editorial: Bardia A, Haber DA: Solidifying Liquid Biopsies: Can Circulating Tumor Cell Monitoring Guide Treatment Selection in Breast Cancer? J Clin Oncol 32(31):3470-3472, 2014. doi: 10.1200/JCO.2014.57.1505. [Epub ahead of print on July 14, 2014] PMID:25024075. J Clin Oncol 32(31):3483-9, 11/2014. e-Pub 6/2014. PMCID: PMC4209100.
3. Mego M, Zuo Z, Gao H, Cohen EN, Giordano A, Tin S, Anfossi S, Jackson S, Woodward W, Ueno NT, Valero V, Alvarez RH, Hortobagyi GN, Khoury JD, Cristofanilli M, Reuben JM. Circulating tumour cells are linked to plasma D-dimer levels in patients with metastatic breast cancer. Thromb Haemost 113(2). e-Pub 11/2014. PMID: 25373787.
4. Budd GT, Barlow WE, Moore HC, Hobday TJ, Stewart JA, Isaacs C, Salim M, Cho JK, Rinn KJ, Albain KS, Chew HK, Burton GV, Moore TD, Srkalovic G, McGregor BA, Flaherty LE, Livingston RB, Lew DL, Gralow JR, Hortobagyi GN. SWOG S0221: A Phase III Trial Comparing Chemotherapy Schedules in High-Risk Early-Stage Breast Cancer. J Clin Oncol. e-Pub 11/2014. PMID: 25422488.
5. Partridge AH, Rumble RB, Carey LA, Come SE, Davidson NE, Di Leo A, Gralow J, Hortobagyi GN, Moy B, Yee D, Brundage SB, Danso MA, Wilcox M, Smith IE. Chemotherapy and Targeted Therapy for Women With Human Epidermal Growth Factor Receptor 2-Negative (or unknown) Advanced Breast Cancer: American Society of Clinical Oncology Clinical Practice Guideline. J Clin Oncol 32(29):3307-29, 10/2014. e-Pub 9/2014. PMID: 25185096.
6. Pusztai L, Moulder S, Altan M, Kwiatkowski D, Valero V, Ueno NT, Esteva FJ, Avritscher R, Qi Y, Strauss L, Hortobagyi GN, Hatzis C, Symmans WF. Gene signature-guided dasatinib therapy in metastatic breast cancer. Clin Cancer Res 20(20):5265-71, 10/2014. e-Pub 8/2014. PMID: 25172932.
7. Elsayegh N, Kuerer HM, Lin H, Gutierrez Barrera AM, Jackson M, Muse KI, Litton JK, Albarracin C, Afrough A, Hortobagyi GN, Arun BK. Predictors that Influence Contralateral Prophylactic Mastectomy Election Among Women with Ductal Carcinoma In Situ Who Were Evaluated for BRCA Genetic Testing. Ann Surg Oncol 21(11):3466-72, 10/2014. e-Pub 5/2014. PMID: 24796968.
8. Parinyanitikul N, Lei X, Chavez-MacGregor M, Liu S, Mittendorf EA, Litton JK, Woodward W, Zhang AH, Hortobagyi GN, Valero V, Meric-Bernstam F, Gonzalez-Angulo AM. Receptor Status Change From Primary to Residual Breast Cancer After Neoadjuvant Chemotherapy and Analysis of Survival Outcomes. Clin Breast Cancer. e-Pub 10/2014. PMID: 25454687.
9. Giuliano M, Giordano A, Jackson S, De Giorgi U, Mego M, Cohen EN, Gao H, Anfossi S, Handy BC, Ueno NT, Alvarez RH, De Placido S, Valero V, Hortobagyi GN, Reuben JM, Cristofanilli M. Circulating tumor cells as early predictors of metastatic spread in breast cancer patients with limited metastatic dissemination. Breast Cancer Res 16(5). e-Pub 9/2014. PMID: 25223629.
10. Hsu YH, Yao J, Chan LC, Wu TJ, Hsu JL, Fang YF, Wei Y, Wu Y, Huang WC, Liu CL, Chang YC, Wang MY, Li CW, Shen J, Chen MK, Sahin AA, Sood A, Mills GB, Yu D, Hortobagyi GN, Hung MC. Definition of PKC-α, CDK6, and MET as therapeutic targets in triple-negative breast cancer. Cancer Res 74(17):4822-35, 9/2014. e-Pub 6/2014. PMCID: PMC4154991.
11. Yardley DA, Noguchi S, Pritchard KI, Burris HA, Baselga J, Gnant M, Hortobagyi GN, Campone M, Pistilli B, Piccart M, Melichar B, Petrakova K, Arena FP, Erdkamp F, Harb WA, Feng W, Cahana A, Taran T, Lebwohl D, Rugo HS. Erratum to: Everolimus Plus Exemestane in Postmenopausal Patients with HR(+) Breast Cancer: BOLERO-2 Final Progression-Free Survival Analysis. Adv Ther 31(9):1008-9, 9/2014. PMID: 25209875.
12. Hayashi N, Manyam GC, Gonzalez-Angulo AM, Niikura N, Yamauchi H, Nakamura S, Hortobágyi GN, Baggerly KA, Ueno NT. Reverse-phase protein array for prediction of patients at low risk of developing bone metastasis from breast cancer. Oncologist 19(9):909-14, 9/2014. e-Pub 8/2014. PMCID: PMC4153464.
13. Woodson AH, Muse KI, Lin H, Jackson M, Mattair DN, Schover L, Woodard T, McKenzie L, Theriault RL, Hortobágyi GN, Arun B, Peterson SK, Profato J, Litton JK. Breast cancer, BRCA mutations, and attitudes regarding pregnancy and preimplantation genetic diagnosis. Oncologist 19(8):797-804, 8/2014. e-Pub 6/2014. PMCID: PMC4122483.
14. Abouharb S, Ensor J, Loghin ME, Katz R, Moulder SL, Esteva FJ, Smith B, Valero V, Hortobagyi GN, Melhem-Bertrandt A. Leptomeningeal disease and breast cancer: the importance of tumor subtype. Breast Cancer Res Treat 146(3):477-86, 8/2014. e-Pub 7/2014. PMID: 25038877.
15. Murthy RK, Varma A, Mishra P, Hess KR, Young E, Murray JL, Koenig KH, Moulder SL, Melhem-Bertrandt A, Giordano SH, Booser D, Valero V, Hortobagyi GN, Esteva FJ. Effect of adjuvant/neoadjuvant trastuzumab on clinical outcomes in patients with HER2-positive metastatic breast cancer. Cancer 120(13):1932-8, 7/1/2014. e-Pub 3/26/2014. PMID: 24677057.
16. Barcenas CH, Niu J, Zhang N, Zhang Y, Buchholz TA, Elting LS, Hortobagyi GN, Smith BD, Giordano SH. Risk of Hospitalization According to Chemotherapy Regimen in Early-Stage Breast Cancer. J Clin Oncol 32(19):2010-7, 7/1/2014. e-Pub 5/27/2014. PMCID: PMC4164758.
17. Lee J, Bartholomeusz C, Mansour O, Humphries J, Hortobagyi GN, Ordentlich P, Ueno NT. A class I histone deacetylase inhibitor, entinostat, enhances lapatinib efficacy in HER2-overexpressing breast cancer cells through FOXO3-mediated Bim1 expression. Breast Cancer Res Treat 146(2):259-72, 7/2014. e-Pub 6/2014. PMCID: PMC4119423.
18. Campos-Gomez S, Valero V, Flores-Arredondo JH, Isassi-Chapa A, Rangel-Rodríguez I, Hortobagyi GN, Gonzalez-Angulo AM. Breast Cancer Subtype and Baseline Characteristics from Diabetic Breast Cancer Patients are Not Different from Nondiabetics. Breast J 20(4):434-6, Jul-Aug, 7/2014. e-Pub 5/26/2014. PMID: 24862358.
19. Fuentes-Mattei E, Velazquez-Torres G, Phan L, Zhang F, Chou PC, Shin JH, Choi HH, Chen JS, Zhao R, Chen J, Gully C, Carlock C, Qi Y, Zhang Y, Wu Y, Esteva FJ, Luo Y, McKeehan WL, Ensor J, Hortobagyi GN, Pusztai L, Fraser Symmans W, Lee MH, Yeung SC. Effects of obesity on transcriptomic changes and cancer hallmarks in estrogen receptor-positive breast cancer. J Natl Cancer Inst 106(7), 7/2014. e-Pub 6/2014. PMCID: PMC4110474.
20. Lacerda L, Reddy JP, Liu D, Larson R, Li L, Masuda H, Brewer T, Debeb BG, Xu W, Hortobágyi GN, Buchholz TA, Ueno NT, Woodward WA. Simvastatin Radiosensitizes Differentiated and Stem-Like Breast Cancer Cell Lines and Is Associated With Improved Local Control in Inflammatory Breast Cancer Patients Treated With Postmastectomy Radiation. Stem Cells Transl Med 3(7):849-56, 7/2014. e-Pub 5/15/2014. PMCID: PMC4073823.
21. McBride A, Allen P, Woodward W, Kim M, Kuerer HM, Drinka EK, Sahin A, Strom EA, Buzdar A, Valero V, Hortobagyi GN, Hunt KK, Buchholz TA. Locoregional Recurrence Risk for Patients with T1,2 Breast Cancer with 1-3 Positive Lymph Nodes Treated with Mastectomy and Systemic Treatment. Int J Radiat Oncol Biol Phys 89(2):392-8, 6/2014. e-Pub 4/2014. PMID: 24721590.
22. Akay CL, Ueno NT, Chisholm GB, Hortobagyi GN, Woodward WA, Alvarez RH, Bedrosian I, Kuerer HM, Hunt KK, Huo L, Babiera GV. Primary tumor resection as a component of multimodality treatment may improve local control and survival in patients with stage IV inflammatory breast cancer. Cancer 120(9):1319-28, 5/2014. e-Pub 2/2014. PMID: 24510381.
23. Gyorffy B, Bottai G, Lehmann-Che J, Kéri G, Orfi L, Iwamoto T, Desmedt C, Bianchini G, Turner NC, de Thč H, André F, Sotiriou C, Hortobagyi GN, Di Leo A, Pusztai L, Santarpia L. TP53 mutation-correlated genes predict the risk of tumor relapse and identify MPS1 as a potential therapeutic kinase in TP53-mutated breast cancers. Mol Oncol 8(3):508-19, 5/2014. e-Pub 1/2014. PMID: 24462521.
24. Yi M, Huo L, Koenig KB, Mittendorf EA, Meric-Bernstam F, Kuerer HM, Bedrosian I, Buzdar AU, Symmans WF, Crow JR, Bender M, Shah RR, Hortobagyi GN, Hunt KK. Which threshold for ER positivity? A retrospective study based on 9639 patients. Ann Oncol 25(5):1004-11, 5/2014. e-Pub 2/2014. PMCID: PMC3999801.
25. Rugo HS, Pritchard KI, Gnant M, Noguchi S, Piccart M, Hortobagyi G, Baselga J, Perez A, Geberth M, Csoszi T, Chouinard E, Srimuninnimit V, Puttawibul P, Eakle J, Feng W, Bauly H, El-Hashimy M, Taran T, Burris HA. Incidence and Time Course of Everolimus-Related Adverse Events in Postmenopausal Women With Hormone Receptor-Positive Advanced Breast Cancer: Insights From BOLERO-2. Ann Oncol 25(4):808-15, 4/2014. e-Pub 3/2014. PMID: 24615500.
26. Henry LN, Hayes DF, Ramsey SD, Hortobagyi GN, Barlow WE, Gralow JR. Promoting Quality and Evidence-Based Care in Early-Stage Breast Cancer Follow-up. J Natl Cancer Inst 106(4):dju034, 4/2014. e-Pub 3/2014. PMID: 24627271.
27. Gagliato DD, Gonzalez-Angulo AM, Lei X, Theriault RL, Giordano SH, Valero V, Hortobagyi GN, Chavez-Macgregor M. Clinical Impact of Delaying Initiation of Adjuvant Chemotherapy in Patients With Breast Cancer. J Clin Oncol 32(8):735-744, 3/2014. e-Pub 1/2014. PMID: 24470007.
28. Gonzalez-Angulo AM, Akcakanat A, Liu S, Green MC, Murray JL, Chen H, Palla SL, Koenig KB, Brewster AM, Valero V, Ibrahim NK, Moulder-Thompson S, Litton JK, Tarco E, Moore J, Flores P, Crawford D, Dryden MJ, Symmans WF, Sahin A, Giordano SH, Pusztai L, Do KA, Mills GB, Hortobagyi GN, Meric-Bernstam F. Open label randomized clinical trial of standard neoadjuvant chemotherapy with paclitaxel followed by FEC vs. the combination of paclitaxel and everolimus followed by FEC in women with triple receptor-negative breast cancer. Ann Oncol. e-Pub 3/2014. PMID: 24669015.
29. Chavez-Macgregor M, Liu S, De Melo-Gagliato D, Chen H, Do KA, Pusztai L, Fraser Symmans W, Nair L, Hortobagyi GN, Mills GB, Meric-Bernstam F, Gonzalez-Angulo AM. Differences in Gene and Protein Expression and the Effects of Race/Ethnicity on Breast Cancer Subtypes. Cancer Epidemiol Biomarkers Prev 23(2):316-23, 2/2014. e-Pub 12/2013. PMCID: PMC3946290.
30. Beck JT, Hortobagyi GN, Campone M, Lebrun F, Deleu I, Rugo HS, Pistilli B, Masuda N, Hart L, Melichar B, Dakhil S, Geberth M, Nunzi M, Heng DY, Brechenmacher T, El-Hashimy M, Douma S, Ringeisen F, Piccart M. Everolimus plus exemestane as first-line therapy in HR(+), HER2 (-) advanced breast cancer in BOLERO-2. Breast Cancer Res Treat 143(3):459-67, 2/2014. e-Pub 12/2013. PMCID: PMC3907668.
31. Thompson LM, Eckmann K, Boster BL, Hess KR, Michaud LB, Esteva FJ, Hortobágyi GN, Barnett CM. Incidence, Risk Factors, and Management of Infusion Related Reactions in Breast Cancer Patients Receiving Trastuzumab. Oncologist. e-Pub 2/2014. PMID: 24536030.
32. Masuda H, Brewer TM, Liu DD, Iwamoto T, Shen Y, Hsu L, Willey JS, Gonzalez-Angulo AM, Chavez-Macgregor M, Fouad TM, Woodward WA, Reuben JM, Valero V, Alvarez RH, Hortobagyi GN, Ueno NT. Long-term treatment efficacy in primary inflammatory breast cancer by hormonal receptor- and HER2-defined subtypes. Ann Oncol 25(2):384-91, 2/2014. e-Pub 12/18/2013. PMCID: PMC3905780.
33. Kai K, Iwamoto T, Kobayashi T, Arima Y, Takamoto Y, Ohnishi N, Bartholomeusz C, Horii R, Akiyama F, Hortobagyi GN, Pusztai L, Saya H, Ueno NT. Ink4a/Arf(-/-) and HRAS(G12V) transform mouse mammary cells into triple-negative breast cancer containing tumorigenic CD49f(-) quiescent cells. Oncogene 33(4):1-9, 1/23/2014. e-Pub 2/4/2013. PMID: 23376849.
34. Gralow JR, Barlow WE, Lew D, Dammann K, Somlo G, Rinn KJ, Vogel SJ, Wong L, Livingston RB, Hortobagyi GN. A phase II study of docetaxel and vinorelbine plus filgrastim for HER-2 negative, stage IV breast cancer: SWOG S0102. Breast Cancer Res Treat 143(2):351-8, 1/2014. e-Pub 12/19/2013. PMCID: PMC3889983.
35. Liu Y, Zhou R, Baumbusch LO, Tsavachidis S, Brewster AM, Do KA, Sahin A, Hortobagyi GN, Taube JH, Mani SA, Aarře J, Wärnberg F, Břrresen-Dale AL, Mills GB, Thompson PA, Bondy ML. Genomic copy number imbalances associated with bone and non-bone metastasis of early-stage breast cancer. Breast Cancer Res Treat 143(1):189-201, 1/2014. e-Pub 12/4/2013. PMID: 24305980.
36. Sohn J, Liu S, Parinyanitikul N, Lee J, Hortobagyi GN, Mills GB, Ueno NT, Gonzalez-Angulo AM. cMET Activation and EGFR-Directed Therapy Resistance in Triple-Negative Breast Cancer. J Cancer 5(9):745-53, 2014. e-Pub 10/2014. PMCID: PMC4216798.
37. Anfossi S, Giordano A, Gao H, Cohen EN, Tin S, Wu Q, Garza RJ, Debeb BG, Alvarez RH, Valero V, Hortobagyi GN, Calin GA, Ueno NT, Woodward WA, Reuben JM. High serum miR-19a levels are associated with inflammatory breast cancer and are predictive of favorable clinical outcome in patients with metastatic HER2+ inflammatory breast cancer. PLoS One 9(1):e83113, 2014. e-Pub 1/2014. PMCID: PMC3885405.
38. Niikura N, Odisio BC, Tokuda Y, Symmans FW, Hortobagyi GN, Ueno NT. Latest biopsy approach for suspected metastases in patients with breast cancer. Nat Rev Clin Oncol 10(12):711-9, 12/2013. e-Pub 10/22/2013. PMID: 24145987.
39. Wang X, Saso H, Iwamoto T, Xia W, Gong Y, Pusztai L, Woodward WA, Reuben JM, Warner SL, Bearss DJ, Hortobagyi GN, Hung MC, Ueno NT. TIG1 Promotes the Development and Progression of Inflammatory Breast Cancer through Activation of Axl Kinase. Cancer Res 73(21):6516-25, 11/1/2013. e-Pub 9/6/2013. PMID: 24014597.
40. Chavez-Macgregor M, Zhang N, Buchholz TA, Zhang Y, Niu J, Elting L, Smith BD, Hortobagyi GN, Giordano SH. Trastuzumab-Related Cardiotoxicity Among Older Patients With Breast Cancer. J Clin Oncol 31(33):4222-8, 11/20/2013. e-Pub 10/14/2013. PMCID: PMC3821011.
41. Masuda H, Baggerly KA, Wang Y, Iwamoto T, Brewer T, Pusztai L, Kai K, Kogawa T, Finetti P, Birnbaum D, Dirix L, Woodward WA, Reuben JM, Krishnamurthy S, Symmans WF, Van Laere SJ, Bertucci F, Hortobagyi GN, Ueno NT. Comparison of Molecular Subtype Distribution in Triple-Negative Inflammatory and Non-inflammatory Breast Cancers. Breast Cancer Res 15(6). e-Pub 11/2013. PMID: 24274653.
42. Toy W, Shen Y, Won H, Green B, Sakr RA, Will M, Li Z, Gala K, Fanning S, King TA, Hudis C, Chen D, Taran T, Hortobagyi G, Greene G, Berger M, Baselga J, Chandarlapaty S. ESR1 ligand-binding domain mutations in hormone-resistant breast cancer. Nat Genet. e-Pub 11/2013. PMID: 24185512.
43. Campone M, Beck JT, Gnant M, Neven P, Pritchard KI, Bachelot T, Provencher L, Rugo HS, Piccart M, Hortobagyi GN, Nunzi M, Heng DY, Baselga J, Komorowski A, Noguchi S, Horiguchi J, Bennett L, Ziemiecki R, Zhang J, Cahana A, Taran T, Sahmoud T, Burris HA. Health-Related Quality of Life and Disease Symptoms in Postmenopausal Women With HR(+), HER2(-) Advanced Breast Cancer Treated With Everolimus Plus Exemestane Versus Exemestane Monotherapy. Curr Med Res Opin 29(11):1463-73, 11/2013. e-Pub 9/4/2013. PMID: 23962028.
44. Masuda H, Baggerly KA, Wang Y, Zhang Y, Gonzalez-Angulo AM, Meric-Bernstam F, Valero V, Lehmann BD, Pietenpol JA, Hortobagyi GN, Symmans WF, Ueno NT. Differential response to neoadjuvant chemotherapy among 7 triple-negative breast cancer molecular subtypes. Clin Cancer Res 19(19):5533-5540, 10/1/2013. e-Pub 8/15/2013. PMID: 23948975.
45. Giordano A, Gao H, Cohen EN, Anfossi S, Khoury J, Hess K, Krishnamurthy S, Tin S, Cristofanilli M, Hortobagyi GN, Woodward WA, Lucci A, Reuben JM. Clinical relevance of cancer stem cells in bone marrow of early breast cancer patients. Ann Oncol 24(10):2515-21, 10/2013. e-Pub 6/2013. PMCID: PMC3784333.
46. Yardley DA, Noguchi S, Pritchard KI, Burris HA, Baselga J, Gnant M, Hortobagyi GN, Campone M, Pistilli B, Piccart M, Melichar B, Petrakova K, Arena FP, Erdkamp F, Harb WA, Feng W, Cahana A, Taran T, Lebwohl D, Rugo HS. Everolimus Plus Exemestane in Postmenopausal Patients with HR(+) Breast Cancer: BOLERO-2 Final Progression-Free Survival Analysis. Adv Ther 30(10):870-84, 10/2013. e-Pub 10/25/2013. PMID: 24158787.
47. Sohn J, Do KA, Liu S, Chen H, Mills GB, Hortobagyi GN, Meric-Bernstam F, Gonzalez-Angulo AM. Functional Proteomics Characterization of Residual Triple-negative Breast Cancer After Standard Neoadjuvant Chemotherapy. Ann Oncol 24(10):2522-6, 10/2013. e-Pub 8/2013. PMCID: PMC3784335.
48. Jiralerspong S, Kim ES, Dong W, Feng L, Hortobagyi GN, Giordano SH. Obesity, Diabetes, and Survival Outcomes in a Large Cohort of Early-stage Breast Cancer Patients. Ann Oncol 24(10):2506-14, 10/2013. e-Pub 6/21/2013. PMCID: PMC3784334.
49. Chen JQ, Bao Y, Lee J, Murray JL, Litton JK, Xiao L, Zhou R, Wu Y, Shen XY, Zhang H, Sahin AA, Katz RL, Bondy ML, Berinstein NL, Hortobagyi GN, Radvanyi LG. Prognostic value of the trichorhinophalangeal syndrome-1 (TRPS-1), a GATA family transcription factor, in early-stage breast cancer. Ann Oncol 24(10):2534-42, 10/2013. e-Pub 5/31/2013. PMCID: PMC3784330.
50. Yao S, Sucheston LE, Zhao H, Barlow WE, Zirpoli G, Liu S, Moore HC, Thomas Budd G, Hershman DL, Davis W, Ciupak GL, Stewart JA, Isaacs C, Hobday TJ, Salim M, Hortobagyi GN, Gralow JR, Livingston RB, Albain KS, Hayes DF, Ambrosone CB. Germline genetic variants in ABCB1, ABCC1 and ALDH1A1, and risk of hematological and gastrointestinal toxicities in a SWOG Phase III trial S0221 for breast cancer. Pharmacogenomics J. e-Pub 9/3/2013. PMID: 23999597.
51. Campone M, Bachelot T, Gnant M, Deleu I, Rugo HS, Pistilli B, Noguchi S, Shtivelband M, Pritchard KI, Provencher L, Burris HA, Hart L, Melichar B, Hortobagyi GN, Arena F, Baselga J, Panneerselvam A, Héniquez A, El-Hashimyt M, Taran T, Sahmoud T, Piccart M. Effect of Visceral Metastases on the Efficacy and Safety of Everolimus in Postmenopausal Women With Advanced Breast Cancer: Subgroup Analysis From the BOLERO-2 Study. Eur J Cancer 49(12):2621-32, 8/2013. e-Pub 6/1/2013. PMID: 23735704.
52. Kim MM, Allen P, Gonzalez-Angulo AM, Woodward WA, Meric-Bernstam F, Buzdar AU, Hunt KK, Kuerer HM, Litton JK, Hortobagyi GN, Buchholz TA, Mittendorf EA. Pathologic complete response to neoadjuvant chemotherapy with trastuzumab predicts for improved survival in women with HER2-overexpressing breast cancer. Ann Oncol 24(8):1999-2004, 8/2013. e-Pub 4/2013. PMCID: PMC3718505.
53. Hershman DL, Unger JM, Crew KD, Minasian LM, Awad D, Moinpour CM, Hansen L, Lew DL, Greenlee H, Fehrenbacher L, Wade JL, Wong SF, Hortobagyi GN, Meyskens FL, Albain KS. Randomized Double-Blind Placebo-Controlled Trial of Acetyl-L-Carnitine for the Prevention of Taxane-Induced Neuropathy in Women Undergoing Adjuvant Breast Cancer Therapy. J Clin Oncol 31(20):2627-33, 7/10/2013. e-Pub 6/3/2013. PMCID: PMC3699727.
54. Abrams JS, Mooney MM, Zwiebel JA, Korn EL, Friedman SH, Finnigan SR, Schettino PR, Denicoff AM, Kruhm MG, Montello M, Misra RR, Ansher SS, DiPiazza KJ, Souhan EM, Wickerham DL, Giantonio BJ, O'Donnell RT, Sullivan DM, Soto NI, Fleming GF, Prindiville SA, Petryshyn RA, Hautala JA, Grad O, Zuckerman BL, Meyer RM, Yao JC, Baker LA, Buckner JC, Hortobagyi GN, Doroshow JH. Implementation of Timeline Reforms Speeds Initiation of National Cancer Institute-Sponsored Trials. J Natl Cancer Inst 105(13):947-953, 7/2013. e-Pub 6/2013. PMCID: PMC3699438.
55. Brewer TM, Masuda H, Liu DD, Shen Y, Liu P, Iwamoto T, Kai K, Barnett CM, Woodward WA, Reuben JM, Yang P, Hortobagyi GN, Ueno NT. Statin use in primary inflammatory breast cancer: a cohort study. Br J Cancer 109(2):318-24, 7/2013. e-Pub 7/2013. PMCID: PMC3721387.
56. Xie X, Bartholomeusz C, Ahmed AA, Kazansky A, Diao L, Baggerly KA, Hortobagyi GN, Ueno NT. Bisphosphorylated PEA-15 Sensitizes Ovarian Cancer Cells to Paclitaxel by Impairing the Microtubule-Destabilizing Effect of SCLIP. Mol Cancer Ther 12(6):1099-111, 6/2013. e-Pub 3/2013. PMCID: PMC3681833.
57. Litton J, Buzdar A, Mac Gregor MC, Gonzalez-Angulo A, Hortobagyi G. Tamoxifen therapy for patients with breast cancer. Lancet 381(9883):2077-8, 6/2013. PMID: 23769223.
58. Eckmann K, Michaud LB, Rivera E, Madden TL, Esparza-Guerra L, Kawedia J, Booser DJ, Green MC, Hortobagyi GN, Valero V. Pilot study to assess toxicity and pharmacokinetics of docetaxel in patients with metastatic breast cancer and impaired liver function secondary to hepatic metastases. J Oncol Pharm Pract. e-Pub 5/2013. PMID: 23676510.
59. Gonzalez-Angulo AM, Liu S, Chen H, Chavez-Macgregor M, Sahin A, Hortobagyi GN, Mills GB, Do KA, Meric-Bernstam F. Functional Proteomics Characterization of Residual Breast Cancer After Neoadjuvant Systemic Chemotherapy. Ann Oncol 24(4):909-16, 4/2013. e-Pub 11/2012. PMCID: PMC3603436.
60. Liedtke C, Hess KR, Karn T, Rody A, Kiesel L, Hortobagyi GN, Pusztai L, Gonzalez-Angulo AM. The Prognostic Impact of Age in Patients with Triple Negative Breast Cancer. Breast Cancer Res Treat 138(2):591-9, 4/2013. e-Pub 3/2013. PMID: 23460246.
61. Burris HA, Lebrun F, Rugo HS, Beck JT, Piccart M, Neven P, Baselga J, Petrakova K, Hortobagyi GN, Komorowski A, Chouinard E, Young R, Gnant M, Pritchard KI, Bennett L, Ricci JF, Bauly H, Taran T, Sahmoud T, Noguchi S. Health-related quality of life of patients with advanced breast cancer treated with everolimus plus exemestane versus placebo plus exemestane in the phase 3, randomized, controlled, BOLERO-2 trial. Cancer 119(10). e-Pub 3/2013. PMID: 23504821.
62. Delpech Y, Coutant C, Hsu L, Barranger E, Iwamoto T, Barcenas CH, Hortobagyi GN, Rouzier R, Esteva FJ, Pusztai L. Clinical benefit from neoadjuvant chemotherapy in oestrogen receptor-positive invasive ductal and lobular carcinomas. Br J Cancer 108(2):285-291, 2/5/2013. e-Pub 1/8/2013. PMCID: PMC3566807.
63. Alvarez RH, Hortobagyi GN. Dual human epidermal growth factor receptor 2 blockade for the treatment of HER2-positive breast cancer. Breast Cancer. e-Pub 2/2013. PMID: 23377763.
64. Gnant M, Baselga J, Rugo HS, Noguchi S, Burris HA, Piccart M, Hortobagyi GN, Eakle J, Mukai H, Iwata H, Geberth M, Hart LL, Hadji P, El-Hashimy M, Rao S, Taran T, Sahmoud T, Lebwohl D, Campone M, Pritchard KI. Effect of Everolimus on Bone Marker Levels and Progressive Disease in Bone in BOLERO-2. J Natl Cancer Inst 105(9). e-Pub 2/2013. PMID: 23425564.
65. Mittendorf EA, Buchholz TA, Tucker SL, Meric-Bernstam F, Kuerer HM, Gonzalez-Angulo AM, Bedrosian I, Babiera GV, Hoffman K, Yi M, Ross MI, Hortobagyi GN, Hunt KK. Impact of Chemotherapy Sequencing on Local-Regional Failure Risk in Breast Cancer Patients Undergoing Breast Conserving Therapy. Ann Surg 257(2):173-9, 2/2013. PMID: 23291658.
66. Bayraktar S, Gutierrez-Barrera AM, Lin H, Elsayegh N, Tasbas T, Litton JK, Ibrahim NK, Morrow PK, Green M, Valero V, Booser DJ, Hortobagyi GN, Arun BK. Outcome of metastatic breast cancer in selected women with or without deleterious BRCA mutations. Clin Exp Metastasis 30(5). e-Pub 2/2013. PMID: 23370825.
67. Zirpoli GR, Brennan PM, Hong CC, McCann SE, Ciupak G, Davis W, Unger JM, Thomas Budd G, Hershman DL, Moore HC, Stewart J, Isaacs C, Hobday T, Salim M, Hortobagyi GN, Gralow JR, Albain KS, Ambrosone CB. Supplement use during an intergroup clinical trial for breast cancer (S0221). Breast Cancer Res Treat 137(3):903-13, 2/2013. e-Pub 1/2013. PMID: 23306462.
68. Dean-Colomb W, Hess KR, Young E, Gornet TG, Handy BC, Moulder SL, Ibrahim N, Pusztai L, Booser D, Valero V, Hortobagyi GN, Esteva FJ. Elevated serum P1NP predicts development of bone metastasis and survival in early-stage breast cancer. Breast Cancer Res Treat 137(2):631-6, 1/2013. e-Pub 12/2012. PMID: 23242617.
69. Giordano A, Egleston BL, Hajage D, Bland J, Hortobagyi GN, Reuben JM, Pierga JY, Cristofanilli M, Bidard FC. Establishment and validation of circulating tumor cell-based prognostic nomograms in first-line metastatic breast cancer patients. Clin Cancer Res. e-Pub 1/2013. PMID: 23340302.
70. Gonzalez-Angulo AM, Chen H, Karuturi MS, Chavez-Macgregor M, Tsavachidis S, Meric-Bernstam F, Do KA, Hortobagyi GN, Thompson PA, Mills GB, Bondy ML, Blumenschein GR. Frequency of mesenchymal-epithelial transition factor gene (MET) and the catalytic subunit of phosphoinositide-3-kinase (PIK3CA) copy number elevation and correlation with outcome in patients with early stage breast cancer. Cancer 119(1):7-15, 1/2013. e-Pub 6/2012. PMCID: PMC3461089.
71. Meric-Bernstam F, Gutierrez-Barrera AM, Litton J, Mellor-Crummey L, Ready K, Gonzalez-Angulo AM, Lu KH, Hortobagyi GN, Arun BK. Genotype in BRCA-associated Breast Cancers. Breast J 19(1):87-91, 1/2013. e-Pub 12/2012. PMID: 23231005.
72. Holder AM, Gonzalez-Angulo AM, Chen H, Akcakanat A, Do KA, Fraser Symmans W, Pusztai L, Hortobagyi GN, Mills GB, Meric-Bernstam F. High stearoyl-CoA desaturase 1 expression is associated with shorter survival in breast cancer patients. Breast Cancer Res Treat 137(1):319-27, 1/2013. e-Pub 12/2012. PMID: 23208590.
73. Ramsey SD, Barlow WE, Gonzalez-Angulo AM, Tunis S, Baker L, Crowley J, Deverka P, Veenstra D, Hortobagyi GN. Integrating comparative effectiveness design elements and endpoints into a phase III, randomized clinical trial (SWOG S1007) evaluating oncotypeDX-guided management for women with breast cancer involving lymph nodes. Contemp Clin Trials 34(1):1-9, 1/2013. e-Pub 9/2012. PMCID: PMC3525786.
74. Chavez-Macgregor M, Clarke CA, Lichtensztajn D, Hortobagyi GN, Giordano SH. Male Breast Cancer According to Tumor Subtype and Race: a Population Based Study. Cancer. e-Pub 1/2013. PMID: 23341341.
75. Esteva FJ, Moulder SL, Gonzalez-Angulo AM, Ensor J, Murray JL, Green MC, Koenig KB, Lee MH, Hortobagyi GN, Yeung SC. Phase I trial of exemestane in combination with metformin and rosiglitazone in nondiabetic obese postmenopausal women with hormone receptor-positive metastatic breast cancer. Cancer Chemother Pharmacol 71(1):63-72, 1/2013. e-Pub 9/2012. PMCID: PMC3536885.
76. Lang JE, Tereffe W, Mitchell MP, Rao R, Feng L, Meric-Bernstam F, Bedrosian I, Kuerer HM, Hunt KK, Hortobagyi GN, Babiera GV. Primary Tumor Extirpation in Breast Cancer Patients who Present with Stage IV Disease Is Associated with Improved Survival. Ann Surg Oncol 20(6). e-Pub 1/2013. PMID: 23306905.
77. Bayraktar S, Gutierrez Barrera AM, Liu D, Pusztai L, Litton J, Valero V, Hunt K, Hortobagyi GN, Wu Y, Symmans F, Arun B. USP-11 as a Predictive and Prognostic Factor Following Neoadjuvant Therapy in Women With Breast Cancer. Cancer J 19(1):10-7, 1/2013. PMID: 23337751.
78. Lynch SP, Lei X, Hsu L, Meric-Bernstam F, Buchholz TA, Zhang H, Hortobágyi GN, Gonzalez-Angulo AM, Valero V. Breast Cancer Multifocality and Multicentricity and Locoregional Recurrence. Oncologist 18(11):1167-73, 2013. e-Pub 10/17/2013. PMID: 24136008.
79. Litton JK, Warneke CL, Hahn KM, Palla SL, Kuerer HM, Perkins GH, Mittendorf EA, Barnett C, Gonzalez-Angulo AM, Hortobágyi GN, Theriault RL. Case control study of women treated with chemotherapy for breast cancer during pregnancy as compared with nonpregnant patients with breast cancer. Oncologist 18(4):369-76, 2013. e-Pub 4/2013. PMCID: PMC3639522.
80. Santarpia L, Iwamoto T, Di Leo A, Hayashi N, Bottai G, Stampfer M, André F, Turner NC, Symmans WF, Hortobágyi GN, Pusztai L, Bianchini G. DNA Repair Gene Patterns as Prognostic and Predictive Factors in Molecular Breast Cancer Subtypes. Oncologist 18(10):1063-73, 2013. e-Pub 9/2013. PMID: 24072219.
81. Hortobágyi G, Conte P. Interpreting cancer biology: refining our therapeutic algorithm in breast cancer. Oncologist 18(4):e8-e10, 2013. PMCID: PMC3639541.
82. Torikoshi Y, Gohda K, Davis ML, Symmans WF, Pusztai L, Kazansky A, Nakayama S, Yoshida T, Matsushima T, Hortobagyi GN, Ishihara H, Kim SJ, Noguchi S, Ueno NT. Novel functional assay for spindle-assembly checkpoint by cyclin-dependent kinase activity to predict taxane chemosensitivity in breast tumor patient. J Cancer 4(9):697-702, 2013. e-Pub 11/2013. PMCID: PMC3842438.
83. Chae YK, Brown EN, Lei X, Melhem-Bertrandt A, Giordano SH, Litton JK, Hortobagyi GN, Gonzalez-Angulo AM, Chavez-Macgregor M. Use of ACE inhibitors and angiotensin receptor blockers and primary breast cancer outcomes. J Cancer 4(7):549-56, 2013. e-Pub 8/2013. PMCID: PMC3753529.
84. Hayashi N, Costelloe CM, Hamaoka T, Wei C, Niikura N, Theriault RL, Hortobagyi GN, Madewell JE, Ueno NT. A Prospective Study of Bone Tumor Response Assessment in Metastatic Breast Cancer. Clin Breast Cancer. e-Pub 10/2012. PMID: 23098575.
85. Meric-Bernstam F, Chen H, Akcakanat A, Do KA, Lluch A, Hennessy BT, Hortobagyi GN, Mills GB, Gonzalez-Angulo AM. Aberrations in translational regulation are associated with poor prognosis in hormone receptor-positive breast cancer. Breast Cancer Res 14(5). e-Pub 10/2012. PMID: 23102376.
86. Dawood S, Lei X, Litton JK, Buchholz TA, Hortobagyi GN, Gonzalez-Angulo AM. Impact of Body Mass Index on Survival Outcome among Women with Early Stage Triple-negative Breast Cancer. Clin Breast Cancer 12(5):364-72, 10/2012. PMID: 23040004.
87. Dawood S, Lei X, Litton JK, Buchholz TA, Hortobagyi GN, Gonzalez-Angulo AM. Incidence of Brain Metastases as a First Site of Recurrence Among Women with Triple Receptor-negative Breast Cancer. Cancer doi: 10.1002/cncr.27434(19):4652-9, 10/2012. e-Pub 2/2012. PMID: 22359359.
88. Cortés J, Calvo E, González-Martín A, Dawood S, Llombart-Cussac A, De Mattos-Arruda L, Gómez P, Silva O, Perez EA, Rugo HS, Lluch A, Hortobagyi GN. Progress against Solid Tumors in Danger: The Metastatic Breast Cancer Example. J Clin Oncol 30(28):3444-7, 10/2012. e-Pub 8/2012. PMID: 22927522.
89. Masuda H, Zhang D, Bartholomeusz C, Doihara H, Hortobagyi GN, Ueno NT. Role of epidermal growth factor receptor in breast cancer. Breast Cancer Res Treat 136(2). e-Pub 10/2012. PMID: 23073759.
90. Chen CT, Du Y, Yamaguchi H, Hsu JM, Kuo HP, Hortobagyi GN, Hung MC. Targeting the IKKβ/mTOR/VEGF Signaling Pathway as a Potential Therapeutic Strategy for Obesity-related Breast Cancer. Mol Cancer Ther 11(10):2212-21, 10/2012. e-Pub 7/2012. PMCID: PMC3712288.
91. Morrow PK, Murthy RK, Ensor JD, Gordon GS, Margolin KA, Elias AD, Urba WJ, Weng DE, Rugo HS, Hortobagyi GN. An Open-Label, Phase II Trial of RPI.4610 (Angiozyme) in the Treatment of Metastatic Breast Cancer. Cancer doi: 10.1002/cncr.26730(17):4098-104, 9/2012. e-Pub 1/2012. PMID: 22281842.
92. Wang Q, Li SH, Wang H, Xiao Y, Sahin O, Brady SW, Li P, Ge H, Jaffee EM, Muller WJ, Hortobagyi GN, Yu D. Concomitant Targeting of Tumor Cells and Induction of T Cell Response Synergizes to Effectively Inhibit Trastuzumab-resistant Breast Cancer. Cancer Res 72(17):4417-4428, 9/2012. e-Pub 7/2012. PMCID: PMC3556997.
93. Delpech Y, Wu Y, Hess KR, Hsu L, Ayers M, Natowicz R, Coutant C, Rouzier R, Barranger E, Hortobagyi GN, Mauro D, Pusztai L. Ki67 expression in the primary tumor predicts for clinical benefit and time to progression on first-line endocrine therapy in estrogen receptor-positive metastatic breast cancer. Breast Cancer Res Treat 135(2):619-27, 9/2012. e-Pub 8/2012. PMID: 22890751.
94. Lynch SP, Lei X, Chavez-MacGregor M, Hsu L, Meric-Bernstam F, Buchholz TA, Zhang A, Hortobagyi GN, Valero V, Gonzalez-Angulo AM. Multifocality and Multicentricity in Breast Cancer and Survival Outcomes. Ann Oncol 23(12). e-Pub 7/2012. PMID: 22776706.
95. Moulder S, Gladish G, Ensor J, Gonzalez-Angulo AM, Cristofanilli M, Murray JL, Booser D, Giordano SH, Brewster A, Moore J, Rivera E, Hortobagyi GN, Tran HT. A phase 1 study of weekly everolimus (RAD001) in combination with docetaxel in patients with metastatic breast cancer. Cancer 118(9):2378-84, 5/2012. e-Pub 10/2011. PMID: 22006179.
96. Burstein HJ, Piccart-Gebhardt MJ, Perez EA, Hortobagyi GN, Wolmark N, Albain KS, Norton L, Winer EP, Hudis CA. Choosing the Best Trastuzumab-Based Adjuvant Chemotherapy Regimen: Should We Abandon Anthracyclines? J Clin Oncol. e-Pub 5/2012. PMID: 22614986.
97. Giordano A, Giuliano M, De Laurentiis M, Arpino G, Jackson S, Handy BC, Ueno NT, Andreopoulou E, Alvarez RH, Valero V, De Placido S, Hortobagyi GN, Reuben JM, Cristofanilli M. Circulating tumor cells in immunohistochemical subtypes of metastatic breast cancer: lack of prediction in HER2-positive disease treated with targeted therapy. Ann Oncol 23(5):1144-50, 5/2012. e-Pub 9/2011. PMID: 21965473.
98. Bayraktar S, Gonzalez-Angulo AM, Lei X, Buzdar AU, Valero V, Melhem-Bertrandt A, Kuerer HM, Hortobagyi GN, Sahin AA, Meric-Bernstam F. Efficacy of neoadjuvant therapy with trastuzumab concurrent with anthracycline- and nonanthracycline-based regimens for HER2-positive breast cancer. Cancer 118(9):2385-93, 5/2012. e-Pub 9/2011. PMCID: PMC3274632.
99. Battula VL, Shi Y, Evans KW, Wang RY, Spaeth EL, Jacamo RO, Guerra R, Sahin AA, Marini FC, Hortobagyi G, Mani SA, Andreeff M. Ganglioside GD2 Identifies Breast Cancer Stem Cells and Promotes Tumorigenesis. J Clin Invest pii: 59735. doi: 10.1172/JCI59735. e-Pub 5/2012. PMCID: PMC3591166.
100. Bartholomeusz C, Gonzalez-Angulo AM, Liu P, Hayashi N, Lluch A, Ferrer-Lozano J, Hortobagyi GN. High ERK Protein Expression Levels Correlate with Shorter Survival in Triple-Negative Breast Cancer Patients. Oncologist. e-Pub 5/2012. PMID: 22584435.
101. Yamauchi H, Woodward WA, Valero V, Alvarez RH, Lucci A, Buchholz TA, Iwamoto T, Krishnamurthy S, Yang W, Reuben JM, Hortobagyi GN, Ueno NT. Inflammatory Breast Cancer: What We Know and What We Need to Learn. Oncologist 17(7). e-Pub 5/2012. PMID: 22584436.
102. De Giorgi U, Mego M, Scarpi E, Giuliano M, Giordano A, Reuben JM, Valero V, Ueno NT, Hortobagyi GN, Cristofanilli M. Relationship Between Lymphocytopenia and Circulating Tumor Cells as Prognostic Factors for Overall Survival in Metastatic Breast Cancer. Clin Breast Cancer 12(4). e-Pub 5/2012. PMID: 22591634.
103. Raghav KP, Wang W, Liu S, Chavez-MacGregor M, Meng X, Hortobagyi GN, Mills GB, Meric-Bernstam F, Blumenschein GR, Gonzalez-Angulo AM. cMET and phospho-cMET protein levels in breast cancers and survival outcomes. Clin Cancer Res 18(8):2269-77, 4/2012. e-Pub 2/2012. PMID: 22374333.
104. Dawood S, Ueno NT, Valero V, Woodward WA, Buchholz TA, Hortobagyi GN, Gonzalez-Angulo AM, Cristofanilli M. Identifying factors that impact survival among women with inflammatory breast cancer. Ann Oncol 23(4):870-5, 4/2012. e-Pub 7/2011. PMID: 21765048.
105. Santarpia L, Qi Y, Stemke-Hale K, Wang B, Young EJ, Booser DJ, Holmes FA, O'Shaughnessy J, Hellerstedt B, Pippen J, Vidaurre T, Gomez H, Valero V, Hortobagyi GN, Symmans WF, Bottai G, Di Leo A, Gonzalez-Angulo AM, Pusztai L. Mutation profiling identifies numerous rare drug targets and distinct mutation patterns in different clinical subtypes of breast cancers. Breast Cancer Res Treat 134(1)(333-343). e-Pub 4/2012. PMID: 22538770.
106. Hayashi N, Nakamura S, Tokuda Y, Shimoda Y, Yagata H, Yoshida A, Ota H, Hortobagyi GN, Cristofanilli M, Ueno NT. Prognostic value of HER2-positive circulating tumor cells in patients with metastatic breast cancer. Int J Clin Oncol 17(2):96-104, 4/2012. e-Pub 6/2011. PMID: 21671160.
107. Niikura N, Liu J, Hayashi N, Palla SL, Tokuda Y, Hortobagyi GN, Ueno NT, Theriault RL. Retrospective analysis of antitumor effects of zoledronic acid in breast cancer patients with bone-only metastases. Cancer 118(8):2039-47, 4/2012. e-Pub 12/2011. PMID: 22139648.
108. Dutta B, Pusztai L, Qi Y, André F, Lazar V, Bianchini G, Ueno N, Agarwal R, Wang B, Shiang CY, Hortobagyi GN, Mills GB, Symmans WF, Balázsi G. A network-based, integrative study to identify core biological pathways that drive breast cancer clinical subtypes. Br J Cancer 106(6):1107-16, 3/2012. e-Pub 2/2012. PMCID: PMC3304402.
109. Morrow PK, Serna R, Broglio K, Pusztai L, Nikoloff DM, Hillman GR, Fontecha M, Li R, Michaud L, Hortobagyi G, Gonzalez-Angulo AM. Effect of CYP2D6 polymorphisms on breast cancer recurrence. Cancer 118(5):1221-7, 3/2012. e-Pub 8/2011. PMID: 21823108.
110. Bayraktar S, Hernadez-Aya LF, Lei X, Meric-Bernstam F, Litton JK, Hsu L, Hortobagyi GN, Gonzalez-Angulo AM. Effect of metformin on survival outcomes in diabetic patients with triple receptor-negative breast cancer. Cancer 118(5):1202-11, 3/2012. e-Pub 7/2011. PMCID: PMC3207034.
111. Li CW, Xia W, Huo L, Lim SO, Wu Y, Hsu JL, Chao CH, Yamaguchi H, Yang NK, Ding Q, Wang Y, Lai YJ, LaBaff AM, Wu TJ, Lin BR, Yang MH, Hortobagyi GN, Hung MC. Epithelial-mesenchymal transition induced by TNF-α requires NF-κB-mediated transcriptional upregulation of Twist1. Cancer Res 72(5):1290-300, 3/2012. e-Pub 1/2012. PMCID: PMC3350107.
112. Iwamoto T, Booser D, Valero V, Murray JL, Koenig K, Esteva FJ, Ueno NT, Zhang J, Shi W, Qi Y, Matsuoka J, Yang EJ, Hortobagyi GN, Hatzis C, Symmans WF, Pusztai L. Estrogen receptor (ER) mRNA and ER-related gene expression in breast cancers that are 1% to 10% ER-positive by immunohistochemistry. J Clin Oncol 30(7):729-34, 3/2012. e-Pub 1/2012. PMID: 22291085.
113. Raghav KP, Hernandez-Aya LF, Lei X, Chavez-Macgregor M, Meric-Bernstam F, Buchholz TA, Sahin A, Do KA, Hortobagyi GN, Gonzalez-Angulo AM. Impact of low estrogen/progesterone receptor expression on survival outcomes in breast cancers previously classified as triple negative breast cancers. Cancer 118(6):1498-506, 3/2012. e-Pub 8/2011. PMCID: PMC3217101.
114. Vahdat LT, Thomas ES, Roché HH, Hortobagyi GN, Sparano JA, Yelle L, Fornier MN, Martín M, Bunnell CA, Mukhopadhyay P, Peck RA, Perez EA. Ixabepilone-associated peripheral neuropathy: data from across the phase II and III clinical trials. Support Care Cancer 20(11). e-Pub 3/2012. PMID: 22382588.
115. Kelly CM, Green MC, Broglio K, Thomas ES, Brewster AM, Valero V, Ibrahim NK, Gonzalez-Angulo AM, Booser DJ, Walters RS, Hunt KK, Hortobagyi GN, Buzdar AU. Phase III Trial Evaluating Weekly Paclitaxel versus Docetaxel in Combination with Capecitabine in Operable Breast Cancer. J Clin Oncol 30(9):930-5, 3/2012. e-Pub 2/2012. PMID: 22331946.
116. Bayraktar S, Elsayegh N, Gutierrez Barrera AM, Lin H, Kuerer H, Tasbas T, Muse KI, Ready K, Litton J, Meric-Bernstam F, Hortobagyi GN, Albarracin CT, Arun B. Predictive factors for BRCA1/BRCA2 mutations in women with ductal carcinoma in situ. Cancer 118(6):1515-22, 3/2012. e-Pub 8/2011. PMID: 22009639.
117. Barcenas CH, Zhang N, Zhao H, Duan Z, Buchholz TA, Hortobagyi GN, Giordano SH. Anthracycline Regimen Adherence in Older Patients with Early Breast Cancer. Oncologist 17(3). e-Pub 2/2012. PMID: 22371383.
118. Raghav KP, Wang W, Liu S, Chavez-MacGregor M, Meng X, Hortobagyi GN, Mills GB, Meric-Bernstam F, Blumenschein GR Jr. Gonzalez-Angulo AM. cMET and Phospho cMET Protein Levels in Breast Cancers and Survival Outcomes. Clin Cancer Res 18(8). e-Pub 2/2012. PMID: 22374333.
119. Schott AF, Barlow WE, Albain KS, Chew HK, Wade JL 3rd, Lanier KS, Lew DL, Hayes DF, Gralow JR, Livingston RB, Hortobagyi GN. Phase II Trial of Simple Oral Therapy with Capecitabine and Cyclophosphamide in Patients with Metastatic Breast Cancer: SWOG S0430. Oncologist 17(2):179-187, 2/2012. PMID: 22267853.
120. Gonzalez-Angulo AM, Iwamoto T, Liu S, Chen H, Do KA, Hortobagyi GN, Mills GB, Meric-Bernstam F, Symmans F, Pusztai L. Gene Expression, Molecular Class Changes and Pathway Analysis After Neoadjuvant Systemic Therapy for Breast Cancer. Clin Cancer Res 18(4). e-Pub 1/2012. PMID: 22235097.
121. Mehta RS, Barlow WE, Albain KS, Vandenberg TA, Dakhil SR, Tirumali NR, Lew DL, Hayes DF, Gralow JR, Livingston RB, Hortobagyi GN. Combination Anastrozole and Fulvestrant in Metastatic Breast Cancer. N Engl J Med 367(5). e-Pub 2012. PMID: 22853014.
122. Giordano SH, Lin YL, Kuo YF, Hortobagyi GN, Goodwin JS. Decline in the User of Anthracyclines for Breast Cancer. J Clin Oncol, 2012. e-Pub 5/2012. PMID: 22614988.
123. Mego M, Gao H, Lee BN, Cohen EN, Tin S, Giordano A, Wu Q, Liu P, Nieto Y, Champlin RE, Hortobagyi GN, Cristofanilli M, Ueno NT, Reuben JM. Prognostic Value of EMT-Circulating Tumor Cells in Metastatic Breast Cancer Patients Undergoing High-Dose Chemotherapy with Autologous Hematopoietic Stem Cell Transplantation. J Cancer 3:369-80, 2012. e-Pub 9/2012. PMID: 23074378.
124. Hortobagyi GN. Toward individualized breast cancer therapy: translating biological concepts to the bedside. Oncologist 17(4):577-84, 2012. e-Pub 4/2012. PMID: 22474069.
125. Hoff AO, Toth BB, Altundag K, Johnson MM, Warneke CL, Hu M, Nooka A, Sayegh G, Guarneri V, Desrouleaux K, Cui J, Adamus A, Gagel RF, Hortobagyi GN. Frequency and risk factors associated with osteonecrosis of the jaw in cancer patients treated with intravenous bisphosphonates. J Bone Miner Res 23(6):826-36, 6/2008. PMID: 18558816.
126. Giordano SH, Kuo YF, Duan Z, Hortobagyi GN, Freeman J, Goodwin JS. Limits of observational data in determining outcomes from cancer therapy. Cancer 112(11):2456-66, 6/2008. PMID: 18428196.
127. Badgwell BD, Giordano SH, Duan ZZ, Fang S, Bedrosian I, Kuerer HM, Singletary SE, Hunt KK, Hortobagyi GN, Babiera G. Mammography before diagnosis among women age 80 years and older with breast cancer. J Clin Oncol 26(15):2482-8, 5/2008. PMID: 18427152.
128. Dawood S, Broglio K, Gong Y, Yang WT, Cristofanilli M, Kau SW, Meric-Bernstam F, Buchholz TA, Hortobagyi GN, Gonzalez-Angulo AM, Gonzalez-Angulo AM. Prognostic significance of HER-2 status in women with inflammatory breast cancer. Cancer 112(9):1905-11, 5/2008. PMID: 18300243.
129. Srokowski TP, Fang S, Duan Z, Buchholz TA, Hortobagyi GN, Goodwin JS, Giordano SH. Completion of adjuvant radiation therapy among women with breast cancer. (Abstracted in Breast Diseases: A Year Book Quarterly 20(3):307-308, 2009. Cancer 113(1):22-29, 4/2008. PMID: 18442124.
130. Bristol IJ, Woodward WA, Strom EA, Cristofanilli M, Domain D, Singletary SE, Perkins GH, Oh JL, Yu TK, Terrefe W, Sahin AA, Hunt KK, Hortobagyi GN, Buchholz TA. Locoregional Treatment Outcomes After Multimodality Management Of Inflammatory Breast Cancer. Int J Radiat Oncol Biol Phys, 4/2008. PMID: 18439768.
131. Tordai A, Wang J, Andre F, Liedtke C, Yan K, Sotiriou C, Hortobagyi GN, Symmans WF, Pusztai L. Evaluation of biological pathways involved in chemotherapy response in breast cancer. Breast Cancer Res 10(2):R37, 2008. PMID: 18445275.
132. Mazouni C, Hall A, Broglio K, Fritsche H, Andre F, Esteva FJ, Hortobagyi GN, Buzdar AU, Pusztai L, Cristofanilli M. Kinetics of serum HER-2/neu changes in patients with HER-2-positive primary breast cancer after initiation of primary chemotherapy. Cancer 109:496-501, 2/2007. e-Pub 2/2007. PMID: 17149760.
133. Buzdar AU, Valero V, Ibrahim NK, Francis D, Broglio KR, Theriault RL, Pusztai L, Green MC, Singletary SE, Hunt KK, Sahin AA, Esteva F, Symmans WF, Ewer MS, Buchholz TA, Hortobagyi GN. Neoadjuvant therapy with paclitaxel followed by 5-fluorouracil, epirubicin, and cyclophosphamide chemotherapy and concurrent trastuzumab in human epidermal growth factor receptor 2-positive operable breast cancer: an update of the initial randomized study population and data of additional patients treated with the same regimen. Clin Cancer Res 13:228-33, 1/2007. PMID: 17200359.
134. Perez EA, Lerzo G, Pivot X, Thomas E, Vahdat L, Bosserman L, Viens P, Mukhopadhyay P, Mullaney B, Peck R, Hortobagyi GN. Efficacy and Safety of Ixabepilone (BMS-247550), a Novel Epothilone Analog, in a Phase II Study of Patients with Advanced Breast Cancer Resistant to and Anthracycline, a Taxane, and Capecitabine. J Clin Oncol 25(23):3407-3414, 2007. e-Pub 7/2007.
135. Gonzalez-Angulo AM, Sahin A, Krishnamurthy S, Yang Y, Kau SW, Hortobagyi GN, Cristofanilli M. Biologic markers in axillary node-negative breast cancer: differential expression in invasive ductal carcinoma versus invasive lobular carcinoma. Clin Breast Cancer 7:396-400, 12/2006. PMID: 17239264.
136. Buzdar AU, Ibrahim NK, Francis D, Booser DJ, Thomas ES, Theriault RL, Pusztai L, Green MC, Arun BK, Giordano SH, Cristofanilli M, Frye DK, Smith TL, Hunt KK, Singletary SE, Sahin AA, Ewer MS, Buchholz TA, Berry D, Hortobagyi GN. Significantly higher pathologic complete remission rate after neoadjuvant therapy with trastuzumab, paclitaxel, and epirubicin chemotherapy: results of a randomized trial in human epidermal growth factor receptor 2-positive operable breast cancer. J Clin Oncol 23(16):3676-85, 6/2005. PMID: 15738535.
137. Cristofanilli M, Gonzalez-Angulo A, Sneige N, Kau SW, Broglio K, Theriault RL, Valero V, Buzdar AU, Kuerer H, Buccholz TA, Hortobagyi GN. Invasive lobular carcinoma classic type: response to primary chemotherapy and survival outcomes. J Clin Oncol 23(1):41-8, 2005. PMID: 15625359.
138. Hortobagyi GN, Ueno NT, Xia W, Zhang S, Wolf JK, Putnam JB, Weiden PL, Willey JS, Carey M, Branham DL, Payne JY, Tucker SD, Bartholomeusz C, Kilbourn RG, De Jager RL, Sneige N, Katz RL, Anklesaria P, Ibrahim NK, Murray JL, Theriault RL, Valero V, Gershenson DM, Bevers MW, Huang L, Lopez-Berestein G, Hung MC. Cationic liposome-mediated E1A gene transfer to human breast and ovarian cancer cells and its biologic effects: a phase I clinical trial. J Clin Oncol 19(14):3422-33, 7/2001. PMID: 11454891.
139. Hortobagyi GN, Buzdar AU, Theriault RL, Valero V, Frye D, Booser DJ, Holmes FA, Giralt S, Khouri I, Andersson B, Gajewski JL, Rondon G, Smith TL, Singletary SE, Ames FC, Sneige N, Strom EA, McNeese MD, Deisseroth AB, Champlin RE. Randomized trial of high-dose chemotherapy and blood cell autografts for high-risk primary breast carcinoma. J Natl Cancer Inst 92(3):225-33, 2/2000. PMID: 10655439.

Grant & Contract Support

Title: Cancer Prevention Agent Development Program: Early Phase Clinical Research
Funding Source: NIH/NCI
Role: Co-Investigator
Principal Investigator: P. Brown
Duration: 9/24/2013 - 9/23/2013
Title: Cancer Center Support (Core) Grant-Project 6-Breast Cancer Program
Funding Source: DHHS/NIH/NCI
Role: Principal Investigator
Duration: 7/1/2013 - 6/30/2018
Title: Breast Cancer Committee Chairman
Funding Source: NCI/Southwest Oncology Group/University of Michigan
Role: Principal Investigator
Duration: 1/1/2013 - 12/31/2013
Title: U10 Full Member Application Affiliated with SWOG
Funding Source: NIH/NCI
Role: Co-Investigator
Principal Investigator: S. Lippman
Duration: 12/1/2010 - 12/1/2015
Title: Development of Novel Strategies of Early Detection and Prevention for HER2+, ER-negative Breast Cancer
Funding Source: Susan G. Komen Breast Cancer Foundation
Role: Co-Investigator
Principal Investigator: D. Yu
Duration: 9/15/2009 - 9/14/2014
Title: Susan G. Komen for the Cure Promise Grant: Development of Novel Early Detection and Prevention Strategies for ER Negative Breast Cancer
Funding Source: Susan G. Komen Breast Cancer Foundation
Role: Investigator
Principal Investigator: D. Yu
Duration: 5/15/2009 - 5/14/2014
Title: Rare and Aggressive Breast Cancer Research Program
Funding Source: State of Texas
Role: Principal Investigator
Duration: 9/1/2007 - 8/31/2013

Last updated: 12/3/2014